Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Apr 29, 2026.

Back to dashboard

Medicare AdvantageAdministrativeLow impact

MA08.085k, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Apr 29, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

Medicare Advantage policy MA08.085k for Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®) has been reissued with an effective date of April 29, 2026. This appears to be a routine policy reissue for this specialty oncology medication used primarily in leukemia treatment.

Action Required

Action needed

By April 29, 2026: Review updated policy MA08.085k for Rylaze® coverage requirements. Oncology billing staff should verify any changes to prior authorization, documentation, or coverage criteria when the full policy details become available.

Related policy hubs

Independence Blue Cross policies Oncology Hematology